Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
DOWNLOAD WHITEPAPER

Levamisole, An Orphan Drug for the Treatment of Nephrotic Syndrome

On 28 October 2005, orphan designation (EU/3/05/324) was granted by the European Commission to ACE Pharmaceuticals BV, The Netherlands, for levamisole hydrochloride for the treatment of nephrotic syndrome.

Levamisole is recommended for use in high-dose steroid-dependent nephrotic syndrome in children, as adjuvant therapy following relapse on corticosteroids such as prednisone; or as an alternative to the use of an alkylating agent or cyclosporin.

In these patients, Levamisole has been shown to induce a significant number of complete remissions, reduce the steroid requirements necessary to induce such a remission, and decrease the incidence of relapse of the disease.



Download to find out more.

Close
Close
Close

Go Top